J4 ›› 2010, Vol. 36 ›› Issue (3): 540-542.

• 临床研究 • 上一篇    下一篇

卵巢癌患者血清人激肽释放酶10的检测及其临床意义

 王翠翠1, 张晓霞1, 王丽娜1, 许淑芬2, 欧健1, 田海涵1   

  1. (1.吉林大学第一医院妇产科|吉林 长春 130021;2.吉林大学第一医院中心实验室|吉林 长春 130021;3.内蒙古自治区通辽市红星医院|内蒙古 通辽 028000)
  • 收稿日期:2009-10-16 出版日期:2010-05-28 发布日期:2010-05-28
  • 通讯作者: 张晓霞 E-mail:zhangxx626@yahoo.com.cn
  • 作者简介:王翠翠(1985-)|女|山东省临沂市人|在读医学硕士|主要从事卵巢癌诊断研究。
  • 基金资助:

    吉林省教育厅基金资助课题(吉教科合字[2005]第132号)

Detection of serum human kallikrein 10 in patients with ovarian cancer and its clinical significance

WANG Cui-Cui1, ZHANG Xiao-Xia1, WANG Li-Na1, HU Chu-Fen2, OU Jian1, TIAN Hai-Han3   

  1. 1.Department of Obstetrics and Gynecology,First Hospital,Jilin University,Changchun 130021,China;2.Central Labotatory,First Hospital,Jilin University,Changchun 130021,China;3.Hong Xing Hospital,Tongliao,Inner Mongolia Autonomous region,Tongliao 028000,China)
  • Received:2009-10-16 Online:2010-05-28 Published:2010-05-28

摘要:

目的:检测卵巢癌患者及其对照组血清人激肽释放酶10(hk10)水平,探讨血清hk10在卵巢癌诊断中的临床意义。方法:ELISA 法检测卵巢癌组(n=50)、卵巢良性肿瘤组(n=20)、妇科良性疾病组(CA125增高,n=26)、妇科其他癌症组(n=18)患者及健康对照组(n=36)血清hk10 水平。结果:卵巢癌组hk10 水平为(15.6±9.23)  μg.L-1,阳性率为88.89%;卵巢良性肿瘤组hk10 水平和阳性率分别为(6.60±2.65) μg.L-1和10.00%;CA125值增高的妇科良性疾病组血清hk10水平和阳性率分别为(6.92±2.97) μg?L-1和15.38%;妇科其他癌症组hk10 水平和阳性率分别为(6.11±2.42) μg.L-1和11.11%;对照组hk10 水平为(6.00±2.26) μg.L-1,阳性率为11.11%;卵巢癌组血清hk10水平和阳性率均显著高于其他各组(P<0.01)。Ⅲ/Ⅳ期卵巢癌组血清hk10水平和阳性率分别为(18.29±9.74) μg.L-1和94.44%,显著高于Ⅰ/Ⅱ期卵巢癌组的(9.87±4.04) μg.L-1和75.00%(P<0.01)。卵巢癌组术后血清hk10水平为(13.83±1.56) μg.L-1,低于术前的hk10水平。 结论:卵巢癌组血清hk10水平显著增高,特异性优于CA125,其有望成为卵巢癌新的肿瘤标志物。

关键词: 人血清激肽释放酶10;卵巢肿瘤;CA125

Abstract:

To detect the serum human kallikrein 10 (hk10) expression in patients with ovarian cancer and control groups,and investigate the clinical significance of hk10 in the diagnosis of ovarian cancer. Methods Enzyme-linked immunoassay (ELISA)mothod was used to detect the hk10 levels in serum in ovarian cancer group(n=50),benign ovarian tumor group(n=20),benign gynecological disease (higher CA125 values,n=26),other malignant gynecological cancer group(n=18) and healthy controls(n=36). Results The level of serum hk10 in the ovarian cancer group was(15.60±9.23) μg.L-1 and the positive rate was 88.89%,in benign ovarian tumor group they were(6.60±2.65) μg.L-1 and 10.00%;in other malignant gynecological cancer group they were(6.11±2.42) μg?L-1 and 11.11%,in healthy control group they were(6.00±2.26) μg.L-1 and 11.11%,the level of serum hk10 and the positive rate in ovarian cancer group were higher than those in other groups(P<0.01).The level of serum hk10 and the positive rate in stage Ⅲ/Ⅳ ovarian cancer group were(18.29±9.74) μg?L-1 and 94.44%,they were significantly higher than those in stage Ⅰ / Ⅱ ovarian cancer group(9.87 μg?L-1±4.04 μg.L-1 and 75.00%)(P<0.01).The level of serum hK10 in patients with ovarian cancer after operation was (13.83±1.56)  μg.L-1 which was lower than before operation.Conclusion The serum hk10 level is significantly increased in ovarian cancer group,its specificity was higher than CA125. hk10 is expected to become a new marker in ovarian cancer.

Key words: human kallikrein 10;ovarian neoplasm;CA125

中图分类号: 

  • R737.31